Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study Meeting Abstract
| Authors: | Cardoso, F.; Juric, D.; Lerebours, F.; Krop, I.; Ruiz Borrego, M.; Neven, P.; Park, Y. H.; Yardley, D.; Jhaveri, K.; Arce, C.; Gu, E.; Akdere, M.; Rugo, H. S. |
| Abstract Title: | Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study |
| Meeting Title: | ESMO Breast Cancer 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2022 May 3-5 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-05-01 |
| Start Page: | S206 |
| End Page: | S207 |
| Language: | English |
| ACCESSION: | WOS:000792494100178 |
| DOI: | 10.1016/j.annonc.2022.03.194 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 175P -- Source: Wos |
